While the ability to deliberately engineer pathogens has been constrained to high-end labs run by top researchers, the technology to achieve this (and other astonishing feats of bioengineering) is rapidly becoming cheaper and more widespread. Such examples include the diminishing cost of sequencing the human genome (from $10 million to $1,000), the accumulation of large datasets of genetic information, the discovery of gene drives, and the discovery of CRISPR.[4] Biotechnology risk is therefore a credible explanation for the Fermi paradox.[5]